124 related articles for article (PubMed ID: 16309589)
1. Decreased levels of advanced glycation end-products in patients with Gilbert syndrome.
Kalousová M; Novotny L; Zima T; Braun M; Vítek L
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(4):387-92. PubMed ID: 16309589
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome.
Vítek L; Kráslová I; Muchová L; Novotný L; Yamaguchi T
J Gastroenterol Hepatol; 2007 Jun; 22(6):841-5. PubMed ID: 17565639
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of advanced glycation end products in children with renal disease.
Sebeková K; Podracká L; Blazícek P; Syrová D; Heidland A; Schinzel R
Pediatr Nephrol; 2001 Dec; 16(12):1105-12. PubMed ID: 11793110
[TBL] [Abstract][Full Text] [Related]
4. Plasma advanced glycation end products are decreased in obese children compared with lean controls.
Sebeková K; Somoza V; Jarcusková M; Heidland A; Podracká L
Int J Pediatr Obes; 2009; 4(2):112-8. PubMed ID: 18645732
[TBL] [Abstract][Full Text] [Related]
5. Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.
van de Kerkhof J; Schalkwijk CG; Konings CJ; Cheriex EC; van der Sande FM; Scheffer PG; ter Wee PM; Leunissen KM; Kooman JP
Nephrol Dial Transplant; 2004 Apr; 19(4):910-6. PubMed ID: 15031349
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end product free adducts are cleared by dialysis.
Agalou S; Ahmed N; Thornalley PJ; Dawnay A
Ann N Y Acad Sci; 2005 Jun; 1043():734-9. PubMed ID: 16037300
[TBL] [Abstract][Full Text] [Related]
7. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
8. The association of advanced glycation end-products with glutathione status.
Sahin E; Göçmen AY; Koçak H; Tuncer M; Gümüslü S
Ann Clin Biochem; 2008 Jul; 45(Pt 4):369-74. PubMed ID: 18583621
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic value of advanced glycation end-products in chronic heart failure.
Hartog JW; Voors AA; Schalkwijk CG; Scheijen J; Smilde TD; Damman K; Bakker SJ; Smit AJ; van Veldhuisen DJ
Eur Heart J; 2007 Dec; 28(23):2879-85. PubMed ID: 17986469
[TBL] [Abstract][Full Text] [Related]
10. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
[TBL] [Abstract][Full Text] [Related]
11. Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis.
Yagmur E; Tacke F; Weiss C; Lahme B; Manns MP; Kiefer P; Trautwein C; Gressner AM
Clin Biochem; 2006 Jan; 39(1):39-45. PubMed ID: 16321365
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end-products in patients with chronic alcohol misuse.
Kalousová M; Zima T; Popov P; Spacek P; Braun M; Soukupová J; Pelinkova K; Kientsch-Engel R
Alcohol Alcohol; 2004; 39(4):316-20. PubMed ID: 15208163
[TBL] [Abstract][Full Text] [Related]
13. Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts.
Nienhuis HL; de Leeuw K; Bijzet J; Smit A; Schalkwijk CG; Graaff R; Kallenberg CG; Bijl M
Rheumatology (Oxford); 2008 Oct; 47(10):1554-8. PubMed ID: 18701539
[TBL] [Abstract][Full Text] [Related]
14. Genomic damage and circulating AGE levels in patients undergoing daily versus standard haemodialysis.
Fragedaki E; Nebel M; Schupp N; Sebekova K; Völkel W; Klassen A; Pischetsrieder M; Frischmann M; Niwa T; Vienken J; Heidland A; Stopper H
Nephrol Dial Transplant; 2005 Sep; 20(9):1936-43. PubMed ID: 15919695
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis.
Kaloudi O; Basta G; Perfetto F; Bartoli F; Del Rosso A; Miniati I; Conforti ML; Generini S; Guiducci S; Abbate R; Pignone A; Castellani S; Livi R; De Caterina R; Matucci-Cerinic M
Rheumatology (Oxford); 2007 Mar; 46(3):412-6. PubMed ID: 16936331
[TBL] [Abstract][Full Text] [Related]
16. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome.
Maruhashi T; Soga J; Fujimura N; Idei N; Mikami S; Iwamoto Y; Kajikawa M; Matsumoto T; Kihara Y; Chayama K; Noma K; Nakashima A; Tomiyama H; Takase B; Yamashina A; Higashi Y
Circulation; 2012 Jul; 126(5):598-603. PubMed ID: 22773454
[TBL] [Abstract][Full Text] [Related]
17. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
18. Detection of elevated N epsilon-carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia.
Rüster M; Franke S; Späth M; Pongratz DE; Stein G; Hein GE
Scand J Rheumatol; 2005; 34(6):460-3. PubMed ID: 16393769
[TBL] [Abstract][Full Text] [Related]
19. Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes.
Nakamura N; Yamazaki K; Satoh A; Urakaze M; Kobayashi M; Yamabe H; Osawa H; Shirato K; Sugawara T; Nakamura M; Tamura M; Okumura K
In Vivo; 2003; 17(2):177-80. PubMed ID: 12792982
[TBL] [Abstract][Full Text] [Related]
20. Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population.
Yamagishi S; Adachi H; Takeuchi M; Enomoto M; Furuki K; Matsui T; Nakamura K; Imaizumi T
Horm Metab Res; 2007 Nov; 39(11):845-8. PubMed ID: 17992643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
